1Todor, IM, 1Lukianova, NYu., 1Rodionova, NK, 2Shevchuk, OO, 1Nikolaev, VG, 1Chekhun, VF
1R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, the NAS of Ukraine, Kyiv
2I.Ya. Horbachevsky Ternopil State Medical University, the MHC of Ukraine, Ternopil
Sci. innov. 2015, 11(2):43-48
https://doi.org/10.15407/scine11.02.043
Section: Research and Engineering Innovative Projects of the National Academy of Sciences of Ukraine
Language: English
Abstract: 

The study is aimed at analyzing myeloprotective effect of new enterosorbents used separately and in combination with two recombinant granulocyte colony stimulating factors: Neupogen (Switzerland) and r-GCSF (Ukraine). The Ukrainian-made r-GCSF has been proved to be as therapeutically efficient as Neupogen (Switzerland); its combined use with C2 enterosorbent significantly increases myeloprotective effect of both GCSF versions.

Keywords: enterosorption, granulocyte colony stimulating factor, myelosupression, tumor
References: 

1. Milijašević B., Stefanović D., Lalić-Popović M. et al. Acute toxic effects of single dose dacarbazine: hematological and histological changes in an animal model. Biotech. Histochem., 2014, 5, pp. 1—8 [in English].
https://doi.org/10.3109/10520295.2014.918653
2. Wensing K.U., Ciarimboli G. Saving ears and kidneys from cisplatin. Anticancer Res., 2013, 33, N 10, pp. 4183—4188 [in English].
3. Qi S., Wu D. Bone marrow-derived mesenchymal stem cells protect against cisplatin-induced acute kidney injury in rats by inhibiting cell apoptosis. Int. J. Mol. Med., 2013, 32, N 6, pp. 1262—1272 [in English].
4. Sardi A., Jimenez W., Nieroda C. et al. Melphalan: a promising agent in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol., 2014, 21, N 3, pp. 908—914 [in English].
https://doi.org/10.1245/s10434-013-3407-6
5. Manko J., Walter-Croneck A., Jawniak D. et al. A clinical comparison of the efficacy and safety of biosimilar GCSF and originator G-CSF in haematopoietic stem cell mobilization. Pharmacol. Rep., 2014, 66, N 2, pp. 239—242 [in English].
https://doi.org/10.1016/j.pharep.2013.09.005
6. Quirion E. Filgrastim and pegfilgrastim use in patients with neutropenia. Clin. J. Oncol. Nurs., 2009, 13, N 3, pp. 324—328 [in English].
https://doi.org/10.1188/09.CJON.324-328
7. Shevchuk O.O., Posokhova E.A., Sakhno L.A. et al. Theoretical ground for adsorptive therapy of anthracyclines cardiotoxicity. Exp. Oncol., 2012, 34, N 4, pp. 314—322 [in English].
8. Sarnatskaya V.V., Sidorenko A.S., Klymchuk D.A. et al. Optimization of physico-chemical properties of carbon enterosorbents and evaluation of their sorption activity for use in the treatment of paraneoplastic syndrome and other endogenous intoxications in cancer patients. Exp. Oncol., 2013, 35, N 2, pp. 83—88 [in English].
9. Sakhno L.A., Yurchenko O.V., Maslenniy V.N. et al. Enterosorption as a method to decrease the systemic toxicity of cisplatin. Exp. Oncol., 2013, 35, N 1, pp. 45—52 [in English].
10. Shevchuk O.O., Posokhova K.A., Sidorenko A.S. et el. The influence of enterosorption on some haematological and biochemical indices of the normal rats after single injection of melphalan. Exp. Oncol., 2014, 36, N 2, pp. 1—7 [in English].